Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma

Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Clin Oncol
Egile Nagusiak: Kamachi, Naoki, Shimose, Shigeo, Hirota, Keisuke, Koya, Shunji, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Hashida, Ryuki, Kawaguchi, Takumi, Matuse, Hiroo, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2021
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7947949/
https://ncbi.nlm.nih.gov/pubmed/33758660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2241
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak